Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.
Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
A Massachusetts man became the first person to try intranasal foralumab under an expanded access program for people with ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results